Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab + tremelimumab with gemcitabine/cisplatin for locally advanced cholangiocarcinoma
2024-518656-23-00Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Sep 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Proportion of cholangiocarcinoma patients at 12 months after surgery and Safety. Started Sep 2023; status: completed.
02
Drugs
durvalumabtremelimumabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-518656-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518656-23-00.